Oxford MediStress wins SBRI contract for WorkWeLCC™ project

New project will see testing of the proprietary LCC™ system in the offshore oil and gas sector

Oxford, UK, 13 September 2023 — Oxford MediStress Ltd, the Oxford-based health and wellness company commercialising the patented Leukocyte CopingCapacity™ (LCC™) system for monitoring stress in the workplace, is pleased to announce that it has been awarded a Small Business Research Initiative (SBRI) contract. The contract will focus on use of the LCC as part of a larger push to improve access to Occupational Health (OH) services, particularly for UK small- and medium-sized enterprises (SMEs).

Oxford MediStress and its partner Divity Health submitted a proposal in response to the “SBRI competition jointly funded by Department for Work and Pensions (DWP) and the Department of Health and Social Care (DHSC): Increasing access to and capacity in Occupational Health: Phase 1” call for proposals earlier this year. Their proposal, titled: “WorkWeLCCplatform to improve access to OH services and improve worker health and work participation in SMEs”, outlines an eight-month project that will include a trial to assess the LCC for use in the offshore oil and gas sector.

The LCC is a groundbreaking diagnostic test which provides a direct way to objectively monitor stress levels, which is important in many high-stress occupations. Using just a single drop of blood taken from a finger prick, OH technicians will now be able to gauge an individual’s stress levels in a ten-minute test that can be conducted on-site.

Dr David Sarphie, Oxford MediStress CEO, stated, “Our primary goal is to make this innovative test user-friendly so that it can be rolled out throughout the Occupational Health sector, transforming the way that employees and individuals who may have stress and anxiety issues are monitored and treated.”

The implications for the offshore oil and gas sector are significant. Use of LCC on a regular basis will help organisations better understand and manage employee stress levels and reduce stress in workers. This is particularly important in high stress conditions like those often faced by oil rig workers.

Oxford MediStress, led by Dr David Sarphie, is actively seeking investment to increase the reach of its commercial team and further its product development efforts, which includes expanding use of LCC for animal welfare and conservation activities, as well. By broadening the test’s reach, the company aims to enhance the well-being of humans and animals alike across the globe.

For more information about the LCC test or potential investment opportunities, please contact Dr David Sarphie; email: admin@oxford-medistress.com.

Back to news page